A key drug for the treatment of leprosy, clofazimine has recently been associated with highly effective and significantly shortened regimens for the treatment of multidrug-resistant tuberculosis (TB). Consequently, we hypothesized that clofazimine may also shorten the duration of treatment for drug-susceptible TB. We conducted a controlled trial in the mouse model of TB chemotherapy comparing the activity of the 6-mo standard regimen for TB treatment, i.e., 2 mo of daily rifampin, isoniazid, pyrazinamide, and ethambutol followed by 4 mo of rifampin and isoniazid, with a 4-mo clofazimine-containing regimen: 2 mo of daily rifampin, isoniazid, pyrazinamide, and clofazimine followed by 2 mo of rifampin, isoniazid, and clofazimine. Treatment efficacy was assessed on the basis of Mycobacterium tuberculosis colony counts in the lungs and spleens during treatment and on the proportion of mice with culture-positive relapse 6 mo after treatment cessation. No additive effect of clofazimine was observed after the first week of treatment, but, by the second week of treatment, the colony counts were significantly lower in the clofazimine-treated mice than in the mice receiving the standard regimen. Lung culture conversion was obtained after 3 and 5 mo in mice treated with the clofazimine-containing and standard regimens, respectively, and relapse-free cure was obtained after 3 and 6 mo of treatment with the clofazimine-containing and standard regimens, respectively. Thus, clofazimine is a promising anti-TB drug with the potential to shorten the duration of TB chemotherapy by at least half (3 mo vs. 6 mo) in the mouse model of TB.
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clofazimine | tuberculosis | mouse model | tuberculosis treatment | experimental chemotherapy C lofazimine is a riminophenazine dye developed in the 1950s by Vincent Barry and colleagues for the treatment of tuberculosis (TB) (1, 2) . Despite being highly active against Mycobacterium tuberculosis in vitro and in mice, a limited number of studies led to the belief that clofazimine would be poorly active in patients with TB (3), and this drug was thus considered not useful for TB treatment. However, clofazimine was subsequently found to be highly effective against multibacillary leprosy and, for decades, has been, and continues to be, one of the key drugs in the World Health Organization (WHO)-recommended multidrug regimen for the treatment of this disease (4) . Because of the increasing frequency of multidrug-resistant (MDR) TB, the search for new active drugs for the treatment of this disease has included a reassessment of the anti-TB activity of clofazimine. As a part of this reassessment, clofazimine was included in several different second-line regimens that were evaluated as possible standardized combinations for the treatment of MDR TB (5) . The most effective regimen identified in this evaluation was a 9-mo, clofazimine-containing drug combination that resulted in an 87.9% relapse-free cure rate, a significant improvement from the WHO-recommended treatment, which is a minimum of 20 mo in duration and associated with only a 48% success rate in patients (6) . Thus, the result of this observational study suggested that the inclusion of clofazimine in a second-line regimen could significantly shorten the duration and improve the outcome of treatment in patients with MDR TB.
To assess the specific contribution of clofazimine to the overall activity of a second-line drug regimen, we conducted an experiment by using a mouse model of MDR TB chemotherapy in which mice infected with an isoniazid-resistant strain of M. tuberculosis (as a surrogate for an MDR strain) were treated with a WHO-recommended second-line regimen with or without clofazimine for 9 mo (7). The lungs of mice that received the clofazimine-free regimen remained highly culture-positive after the 9 mo of treatment; to the contrary, the lungs of mice that received the clofazimine-containing regimen were culture-negative after only 5 mo of treatment, with 82% relapse-free cure in mice treated for 5, 6, 7, 8, or 9 mo. These data, which were in strong agreement with the observational study conducted in patients with MDR TB, clearly demonstrated that the addition of clofazimine to a second-line regimen increased the bactericidal activity of the regimen and drastically shortened the duration of treatment necessary to achieve cure. These striking findings led to the question whether clofazimine could have a similar impact when included in the first-line regimen for drugsusceptible TB, which represents the bulk of the global TB burden. Of the estimated 8.6 million new TB cases that occurred
Significance
The infectious disease tuberculosis (TB) is a major public health problem that affects millions of people worldwide. TB treatment consists of a multidrug regimen that needs to be taken for a minimum of 6 mo, and lack of adherence to this regimen is associated with treatment failure and emergence of drug resistance. In a mouse model of TB chemotherapy, we have found that inclusion of the antileprosy drug clofazimine in the first-line regimen for TB reduces the duration of treatment necessary to achieve relapse-free cure from 6 mo to 3 mo. Our data suggest that clofazimine, a drug already known to be safe for long-term administration to patients with leprosy, has the potential to significantly shorten the duration of TB treatment.
in 2012, more than 8.1 million (>94%) were drug-susceptible TB (8) , and, because of the 6-mo duration of the standard treatment for drug-susceptible TB, lack of adherence to this regimen is the main cause of the development of drug-resistant TB. Therefore, shortening the duration of the first-line regimen could have a significant impact on the development of MDR TB. Therefore, by using the mouse model of (drug-susceptible) TB, we designed a study to test the hypothesis that the inclusion of clofazimine in the first-line drug regimen would, as it did for the drug treatment for MDR TB, increase the bactericidal activity of the regimen and decrease the duration of treatment necessary to achieve relapse-free cure.
Results
Establishment of Infection. To assess the bactericidal and sterilizing activity of the first-line regimen, we infected 223 female BALB/c mice by aerosol with M. tuberculosis strain H37Rv, achieving a mean implantation of 2.62 (SD 0.44) log 10 cfus in the lungs, with the spleens being culture-negative the day after infection. Our objective was to establish a heavy infection with high cfu counts in the lungs and the spleens; as such, our original protocol was to initiate treatment 6 wk after infection. However, by 4 wk after infection, 12 mice had already died and all remaining mice were sick; therefore, we began treatment at 4 wk postinfection. An additional 10 mice died during the first 4 d of treatment. To compensate for this loss of mice, we reduced the numbers of mice killed on day 0 (the day of treatment initiation) as well as at some of the relapse assessment time points (detailed in Materials and Methods). As a consequence of the gravity of the disease at the start of treatment, the pulmonary lesions were extensive ( Fig. 1) , and the bacterial burden was extremely high in the lungs and spleens, with means of 9.02 (SD 0.37) and 5.67 (SD 0.24) log 10 cfu in each organ, respectively (Table S1 ).
Early Bactericidal Activity. At day 0, treatment was initiated with the control 6-mo standard regimen (a 2-mo intensive phase of daily rifampin, isoniazid, pyrazinamide, and ethambutol followed by a 4-mo continuation phase of daily rifampin and isoniazid) or a 4-mo test regimen, in which clofazimine was used in place of ethambutol during the intensive phase and added to rifampin and isoniazid during a 2-mo continuation phase. After 1 wk of treatment, the log 10 cfu counts for the mice receiving the standard regimen had decreased to 7.04 (SD 0.63) and 4.06 (SD 0.38) in the lungs and spleens, respectively; the log 10 cfu counts were very similar in lungs and spleens of mice receiving the clofazimine-containing regimen, at 7.26 (SD 0.30) and 3.50 (SD 0.13), respectively ( Fig. 2 A and B and Table S1 ). Thus, the 7-d early bactericidal activity (EBA 0-7 ), defined as the decrease in log 10 cfu per lung per day of treatment, was not different between the two treatment groups: 0.283 for the standard regimen and 0.251 for the clofazimine-containing regimen (Table 1) . There were also no differences in lung gross pathologic findings between mice from the control and test treatment groups (Fig.  1) . However, after 2 wk of treatment, the clofazimine-treated mice had significantly lower log 10 cfu counts than the mice treated with the standard regimen: 4.01 (SD 0.74) compared with 6.02 (SD 0.21) in the lungs (P < 0.0001) and 2.81 (SD 0.24) compared with 3.53 (SD 0.21) in the spleens (P < 0.0001). Thus, the EBA over the first 2 wk was greater for the clofaziminecontaining regimen (EBA 0-14 : 0.358) than for the standard regimen (EBA 0-14 : 0.214), and the difference in EBA during the second week of treatment was much greater: EBA 7-14 of 0.465 for the clofazimine-containing regimen vs. EBA 7-14 of 0.146 for its clofazimine-free counterpart (Table 1 ). This increased bactericidal activity of the clofazimine-containing regimen during the second week of treatment was also evident on gross pathologic examination, in which the mice receiving this regimen already had fewer visible lung lesions ( Fig. 1 ).
cfu Count Decline Throughout Treatment. During the 8-wk intensive phase of treatment, the bactericidal activity in the lungs and spleens was significantly greater for mice receiving the clofaziminecontaining regimen than the standard regimen (P = 0.0001 for the difference in lungs and P < 0.05 for the difference in spleens; Fig. 2C ). The reduction in cfu counts during treatment was also statistically different between the lungs and spleens regardless of the treatment regimen (P < 0.01 for the difference with the standard regimen and P < 0.001 for the difference with the clofazimine-containing regimen). Mice receiving the clofaziminecontaining regimen were already becoming culture-negative by the start of the continuation phase; the lungs from two mice were culture-negative, and lungs from the remaining three mice were culture-positive with 2, 8, and 19 cfus in the lungs; the spleens of all mice in this group were culture-negative (Table S1 ). One month into the continuation phase (week 12), all mice receiving clofazimine were culture-negative. As expected, mice receiving the standard, clofazimine-free regimen were still culture-positive The duration of treatment is indicated on the left. 2RHZE, 2 mo of daily rifampin (marked as "R"), isoniazid ("H"), pyrazinamide ("Z"), and ethambutol ("E"). 2RHZC, 2 mo of daily rifampin, isoniazid, pyrazinamide, and clofazimine ("C"). Gross pathologic appearance of lungs after 2 mo of treatment are presented in Fig. S1 . Daily drug doses were 10 mg/kg for isoniazid and rifampin, 150 mg/kg for pyrazinamide, 100 mg/kg for ethambutol, and 25 mg/kg for clofazimine.
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after 16 wk of treatment (with 1, 1, and 2 cfus in 3 of 5 mouse lungs); all mice in this group were culture-negative at month 5, i.e., 3 mo into the continuation phase (week 20). In both treatment groups, the decrease in lung cfu counts was associated with a decrease in the appearance of gross lung lesions; however, the lungs of the clofazimine-treated mice became discolored, becoming darker with increasing time of clofazimine administration ( Fig. 1 and Fig. S1 ).
Assessment of Relapse. For mice that received the standard firstline regimen, relapse was assessed 6 mo after completing 16, 20, or 24 wk of treatment. Among mice treated for 16 wk (4 mo), 5 of 15 (33%) were culture-positive (Table 2) , with four of the mice having innumerable cfus in the lungs and spleen, and one mouse having only one single colony in the lungs and no cfus in spleen. Among mice treated for 20 wk (5 mo), 3 of 15 (20%) had culture-positive lungs with confluent bacterial growth on agar plates, but only 2 of these mice had culture-positive spleens. Finally, among mice treated for 24 wk (6 mo), still 1 mouse among the 10 that were kept for relapse yielded 5 colonies from the lung culture and none from the spleen. For mice treated with the clofazimine-containing regimen, relapse was assessed 6 mo after completing 8, 12, or 16 wk of treatment. Among mice treated for 8 wk (2 mo), 8 of 15 mice (53%) had culture-positive lungs with more than 100 colonies, but only 4 of the mice also had culture-positive spleens, all with 100 colonies or less. No relapses were observed in mice treated for 12 or 16 wk (3 or 4 mo, respectively), as not one single lung or spleen culture was positive. Regardless of the duration of treatment, the red discoloration of the lungs had completely disappeared at the time of relapse assessment (Fig. S2 ).
Pharmacokinetics. In mice treated with the clofazimine-containing regimen, the serum concentration of clofazimine was approximately 1.5 μg/mL after completion of 2 mo of treatment and was slightly lower, approximately 1.2 μg/mL, on completion of 3 and 4 mo of treatment (Table 3) . Six months after the cessation of treatment, the concentration in the serum was below the lower limit of detection in all mice, regardless of the duration of clofazimine administration. In the tissues, clofazimine concentrations were much higher than in the serum, with a tendency to increase with duration of administration but with large variations between individual mice. In the lungs, concentrations increased from approximately 100 μg/g after 2 mo of treatment to 300 μg/g at month 3, and then decreased to approximately 150 μg/g after 4 mo. In the spleens, clofazimine concentrations were 10, 30, and 400 μg/g after 2, 3, and 4 mo of treatment, respectively. In the livers, the concentrations slightly increased from months 2 to 4 but remained close to the 50 μg/g level. Six months after cessation of treatment administered for 2 mo, the clofazimine concentrations in all organs had decreased below the minimum inhibitory concentration of clofazimine for M. tuberculosis (0.25 μg/mL), except in the spleens, where the concentration was surprisingly higher than what was detected at the end of treatment. Six months A B C Fig. 2 . The effect of treatment on cfu counts in the lungs and spleens of M. tuberculosis-infected mice: (A) mean cfu counts in mouse lungs and (B) mean cfu counts in the mouse spleens the day after infection (month −1), the day of treatment initiation (day 0), and during the course of treatment. The timing of the 0 cfu count in the spleen has been adjusted to when dissemination to the spleen should have occurred (i.e., when the log 10 cfu count in the lungs reached approximately 10 5 ), to more accurately reflect the bacterial burden in this organ. Error bars represent SD. (C) Nonlinear regression of the decrease in the cfu counts in the lungs and spleens during the first 8 wk of treatment. 2RHZE/4RH, 2 mo of daily rifampin (marked as "R"), isoniazid ("H"), pyrazinamide ("Z"), and ethambutol ("E"), followed by 4 mo of daily rifampin and isoniazid. 2RHZC/2RHC, 2 mo of daily rifampin, isoniazid, pyrazinamide, and clofazimine ("C"), followed by 2 mo of daily rifampin, isoniazid, and clofazimine. Daily drug doses were 10 mg/kg for isoniazid and rifampin, 150 mg/kg for pyrazinamide, 100 mg/kg for ethambutol, and 25 mg/kg for clofazimine. EBA is defined as the decline in log 10 cfu per lung per day during the first week (days 0-7), the second week (days 7-14), or the first 2 wk (days 0-14) of treatment. All untreated control mice died by week 2. Daily drug doses were as follows: 10 mg/kg for rifampin (R) and isoniazid (H), 150 mg/kg for pyrazinamide (Z), 100 mg/kg for ethambutol (E), and 25 mg/kg for clofazimine (C).
after stopping treatment administered for 3 mo, clofazimine levels were below the lower limit of detection for two of three mice but were especially high in the lung of one mouse, emphasizing the great individual variations. Six months after cessation of treatment that was administered for 4 mo, the clofazimine concentrations in the tissues were still detectable, at approximately 2.0, 7.5, and 0.5 μg/g in the lungs, spleen, and liver, respectively.
Drug Carryover. Because clofazimine accumulates to such high levels in the tissues, the drug carryover from the homogenized lungs and spleens can prevent growth on agar plates, causing artificially low cfu counts. To detect and minimize the impact of any drug carryover effect from this experiment, lung and spleen homogenates from the clofazimine-treated mice were plated in parallel on plain 7H11 selective agar and on 7H11 selective agar supplemented with 0.4% activated charcoal (to adsorb the drug). After the first week of treatment, some carryover of clofazimine was observed on the culture plates inoculated with the undiluted tissue homogenates, but not on the subsequent dilutions (Tables  S2 and S3 ). After 2 wk of treatment, carryover was observed with undiluted and 10 −1 dilutions of the tissue homogenates. After the first month of treatment, the carryover of clofazimine completely prevented growth on the plain culture plates inoculated with the undiluted tissue homogenates, and there was even poor growth or sometimes no growth at all on the charcoal plates inoculated with neat lung homogenates, indicating that the charcoal could not fully neutralize the drug at such high tissue concentrations (Table S2). This effect was not observed with the neat spleen homogenates inoculated on charcoal-containing plates (Table  S3) . At relapse assessment (6 mo after stopping treatment), lung and spleen cultures yielded similar growth on plain and charcoalcontaining plates; thus, there was no carryover effect (Table S4) .
Discussion
The results from the present study show that lung culture conversion and relapse-free cure were obtained much earlier in mice treated with the test, clofazimine-supplemented first-line regimen for TB than in mice treated with the control standard regimen. Clofazimine-treated mice were all culture-negative by 3 mo whereas control mice required 5 mo of treatment to become culture-negative, and there were no relapses among mice treated with the clofazimine-containing regimen for 3 or 4 mo. These results indicate the potential of clofazimine-containing regimens to shorten the duration of treatment for drug-susceptible TB in humans and thus deserve in-depth critical assessment.
Firstly, the possibility of technical errors should be considered. In fact, no finding can suggest an abnormality in the response of mice to treatment. The response to the control regimen was usual because all mice were rendered culture-negative by month 5 of treatment ( Fig. 2 and Table S1), with 6-mo relapse rates of 20% in mice treated for 5 mo and 10% in mice treated for 6 mo (Table 2) , a common observation when the bacillary burden is very high at the time of treatment initiation (9) . As for the clofazimine-containing regimen, its activity fits well with the previous observation that lung culture conversion was obtained much more rapidly in mice treated with a clofazimine-containing second-line regimen than in mice treated with the same regimen without clofazimine (7). However, there is always the possibility that the apparent culture-negative status observed in the clofazimine-treated mice after 3 mo was artificial and caused by carryover of clofazimine that had accumulated in the tissues. The relapse assessment after stopping treatment is the only way to determine whether culture conversion during treatment corresponds to a real killing of the bacteria. To ensure true assessment of culture conversion, we waited for 6 mo (rather than the standard 3 mo) after stopping treatment before relapse assessment. In this study, among mice treated with the clofaziminecontaining regimen for only 2 mo, two of five were already culture-negative, and 6 mo later, after treatment cessation, 7 of 15 mice (45%) were culture-negative, suggesting that those that were culture-negative at month 2 were already cured. Among mice treated with the clofazimine-containing regimen for 3 or 4 mo, all mice were culture-negative at the end of treatment, and, additionally, all mice were culture-negative 6 mo after stopping treatment, suggesting that all mice were indeed cured after treatment for 3 mo. Thus, it seems that clofazimine is a remarkable bactericidal drug, or at least strongly potentiates the bactericidal activity of the isoniazid, rifampin, and pyrazinamide combination.
It is surprising that such powerful bactericidal properties are not associated with EBA, i.e., bacterial killing during the first days of treatment. In this study, we observed that the regimen in which ethambutol was replaced by clofazimine had absolutely no superior bactericidal effect vs. the standard ethambutolcontaining regimen during the first 7 d of treatment, with the former being associated with a decrease of 1.76 and the latter a decrease of 1.98 in log 10 cfu counts in the mouse lungs ( Fig. 2A and Table 1 ). However, during the second week of treatment, the clofazimine-containing regimen was significantly more bactericidal than the standard regimen; mice receiving clofazimine experienced a 3.25 log 10 decrease in lung cfu counts, whereas the cfu counts in the lungs of mice receiving the standard regimen decreased by 1.02 log 10 . Therefore, clofazimine clearly had potent, Relapse is defined as having culture-positive lungs or spleens at the time of assessment. 2RHZE/4RH, 2 mo of daily rifampin (R), isoniazid (H), pyrazinamide (Z), and ethambutol (E), followed by 4 mo of daily rifampin and isoniazid. 2RHZC/2RHC, 2 mo of daily rifampin, isoniazid, pyrazinamide, and clofazimine (C), followed by 2 mo of daily rifampin, isoniazid, and clofazimine. Values presented as mean (SD). The lower limit of detection was 0.048 μg/mL or μg/g. *The clofazimine concentration was below the lower limit of detection in the tissues from two of three mice.
14-d extended EBA, with all bactericidal activity occurring during the second week of treatment. Such an observation may have contributed, at least in part, to the negative appraisal of clofazimine activity in the treatment of patients with TB in the 1950s and 1960s, and may be related to its mechanism of action involving the respiratory chain of M. tuberculosis (10), curiously like bedaquiline (11) , which also exhibits limited EBA that is not evident until at least 4-5 d of treatment (12) .
In assessing the effectiveness of the clofazimine-containing drug regimen, it was not possible to specifically appreciate the possible benefit of sustained drug concentrations. We have confirmed the well-known tissue accumulation (2, 13-15) and its negative effect of discoloration ( Fig. 1 and Fig. S1 ) and carryover (Tables S2 and S3 ). However, we do not know whether sustained drug concentrations after treatment cessation contribute to sustained antimicrobial activity; that is, whether 2 and 3 mo of drug administration are not followed by several supplementary weeks or months of clofazimine exposure and antimicrobial activity. We know only that 6 mo after cessation of treatment for 2, 3, or 4 mo, the serum concentrations of clofazimine are below the lower limit of detection and are certainly not contributing to the overall antimicrobial activity. The concentrations of clofazimine in the organs remained measurable (Table 3 ) but were no longer inducing discoloration (Fig. S2) or carryover (Table S4 ). However, it is certainly possible that drug accumulation has some therapeutic benefit, and further experiments should aim at measuring the degree of this effect. A difficulty in this matter is the difference in the clofazimine concentrations between individual mice, which may be related to the extent of inflammation in the lesions, as clofazimine has been shown to accumulate in macrophages (16) , and the redistribution of the drug in the mouse body, as has been well-demonstrated (17) .
Recently, Irwin et al. reported that clofazimine (administered as monotherapy) exhibited decreased activity against M. tuberculosis in the lungs of C3HeB/FeJ mice compared with the lungs of BALB/c mice (18) . They observed that this decrease in antimicrobial activity was associated with the presence of hypoxic pulmonary granulomas with caseous necrosis in the C3HeB/FeJ mice; these granulomas often harbor extracellular M. tuberculosis (19) . Such lesions are not formed in BALB/c mice, where the bacilli remain largely intracellular. Because clofazimine accumulates within macrophages as crystals or liquid crystals (16, 20, 21) , the issue was raised that the anti-M. tuberculosis activity of clofazimine could be overestimated in the BALB/c model. However, the drugs isoniazid, rifampin, and pyrazinamide, which are not known to accumulate within macrophages, have also been shown to have significantly decreased antimicrobial activity in M. tuberculosis-infected C3HeB/FeJ mice compared with BALB/c mice (19) , and standard and novel combination regimens have also been reported to be less effective in C3HeB/FeJ mice than in BALB/c mice (22) . Although not considered to be generally immune-deficient, C3HeB/FeJ mice are more susceptible to infection with M. tuberculosis than BALB/c mice (9, 19, 22) , and are also more prone to the selection of drugresistant bacilli during treatment than are BALB/c mice (9, 19) . These characteristics are similar to what has been observed in M. tuberculosis-infected nude mice, which are also highly susceptible to infection, less responsive to therapy, and more prone to the selection of drug-resistant bacilli than BALB/c mice (23) . Taken together, the data from these different studies suggest that the antimicrobial activity of clofazimine, like that of other anti-TB drugs, is complemented by the host immune response against infection; thus, it will also be important to evaluate the effectiveness of clofazimine-containing regimens in the context of an immune-deficient host.
Because clofazimine is a drug that has been safely and successfully administered to millions of patients with leprosy (4) , and the results we have observed with clofazimine in M. tuberculosisinfected mice are so promising, it seems advisable to rationally assess the contribution of clofazimine as a first-line drug in the treatment of human TB. A reasonable approach could include the substitution of clofazimine for ethambutol in the standard first-line regimen for TB in a serial sputum colony count study (usually referred to as an SSCC study) (24) and certainly not in an EBA study because of clofazimine's well-established lack of EBA against M. tuberculosis. Considering that, in much of the world, TB is highly associated with HIV infection, additional experimental chemotherapy studies should also be performed to assess the impact of host immune deficiency on the efficacy of any clofazimine-containing regimen.
Materials and Methods
All work with live bacteria was performed in a biosafety level-3 laboratory, and all work with animals was performed in an animal biosafety level-3 facility. All animal procedures were approved by the Johns Hopkins University Animal Care and Use Committee.
Aerosol Infection. Six-week-old female BALB/c mice (N = 223) purchased from Charles River were aerosol-infected using a 7H9 broth culture of M. tuberculosis strain H37Rv (American Type Culture Collection no. 27294). When the culture reached an OD 600 of 1.0, it was diluted 1:15 in PBS solution, which corresponded to 6.5 log 10 cfu/mL; this bacterial suspension was used for aerosol infection (in two infection runs) as previously described (25) . After infection, mice were randomized into treatment groups. Pretreatment, 10 mice (n = 5 from each infection run) were killed the day after infection to determine lung cfu implantation, and five mice were killed on the day of treatment initiation (day 0) to determine the baseline pretreatment cfu counts in the lungs and spleens. The original experiment design included 10 mice (n = 5 per infection run) to be killed at day 0, but, because mice were dying/becoming moribund before day 0, this number was reduced to 5. Pretreatment quantitative lung and spleen cultures were performed on selective 7H11 agar plates as previously described (7). Drug Treatment. Treatment began 4 wk after infection with one of the following regimens: (i) negative control (25 mice), no drug; (ii) positive control (85 mice), standard first-line regimen composed of 2 mo of daily rifampin, isoniazid, pyrazinamide, and ethambutol followed by 4 mo of daily rifampin and isoniazid; and (iii) test regimen (93 mice), 2 mo of daily rifampin, isoniazid, pyrazinamide, and clofazimine followed by 2 mo of daily rifampin, isoniazid, and clofazimine. For the test regimen, the continuation phase was reduced to 2 mo (compared with the 4-mo continuation phase of the standard regimen) because we were specifically interested in the treatmentshortening activity of clofazimine; thus, it was not of interest to test a regimen longer than 4 mo in total duration.
Drugs were administered daily (5 d per week, Monday to Friday) by oral gavage. Rifampin was prepared in distilled water for administration as a single dose in 0.2 mL, which was administered at least 1 h before the administration of isoniazid/pyrazinamide or isoniazid/pyrazinamide/ethambutol, which were prepared together in distilled water to be administered as a single dose in 0.2 mL. At least 1 h after the administration of isoniazid/ pyrazinamide, clofazimine, prepared as a suspension in 0.05% (wt/vol) agarose, was administered in a single dose of 0.2 mL. Daily drug doses (rifampin, 10 mg/kg; isoniazid, 10 mg/kg; pyrazinamide, 150 mg/kg; ethambutol, 100 mg/kg; clofazimine, 25 mg/kg) were chosen to produce area under the serum concentration curve values similar to those obtained with currently recommended human doses (7, 26) . All drugs were purchased from Sigma.
Assessment of Treatment Efficacy. Treatment efficacy was assessed on the basis of quantitative lung and spleen cfu counts during treatment and the proportion of mice with culture-positive relapse 6 mo after treatment cessation. During treatment, groups of five mice from each treatment group were killed for lung and spleen cfu count assessment after 1, 2, 4, 8, 12, 16, 20, and 24 wk (as applicable) of drug administration; fewer mice were included in the no-drug control group as they were expected to become moribund in the early weeks following treatment initiation. For control mice, quantitative lung and spleen cultures were performed on selective 7H11 agar. To detect and limit the consequences of clofazimine carryover, quantitative lung and spleen culture for test (i.e., clofazimine-treated) mice, were performed on plain and 0.04% (wt/vol) activated charcoal-containing 7H11 selective agar plates as previously described (7). The colony counts used to determine the log 10 cfu counts per lung were from the plain or charcoal-containing plates, whichever had the higher colony count.
For the mice receiving the standard first-line regimen, groups of 15, 15, and 10 mice were withdrawn from treatment after 16, 20, and 24 wk of administration, respectively; these mice were then kept for relapse assessment 6 mo after stopping treatment. Similarly for the mice receiving the clofazimine-containing regimen, groups of 15, 15, and 15 mice were withdrawn from treatment after 8, 12, and 16 wk of administration, respectively, and kept an additional 6 mo for relapse assessment. The planned experiment included 15 mice in each relapse assessment subgroup; however, the subgroup receiving the longest duration of treatment from the standard regimen was reduced to 10 mice to compensate for the loss of mice before the start of treatment. To assess relapse after treatment cessation, lung and spleen homogenates were inoculated onto plain (and charcoal-containing for the test mice) plates as previously described (7).
Pharmacokinetic Analysis. For the mice receiving the clofazimine-containing regimen, three mice were killed (in addition to the five mice that were killed for cfu counting) at weeks 8, 12, and 16 of treatment for the measurement of clofazimine concentrations in the serum and tissues. Three additional mice were also killed at the time of relapse assessment for clofazimine concentration determination. Following exsanguination, blood samples were kept at room temperature for at least 10 min before spinning at maximum speed in a microcentrifuge for 10 min. The separated serum was removed and dispensed in sterile microcentrifuge tubes. For clofazimine measurement, the serum was stored at −80°C until analysis. The lungs, liver, and spleen from each mouse were removed immediately after blood collection, placed in 2.5 mL PBS solution, kept at 4°C for 48 h, and then homogenized in glass homogenizers.
For determination of drug concentration in the serum and tissue homogenates, 100 μL of each prepared sample was added to 100 μL of water and 400 μL of acetonitrile, vortexed for 15 s, and then centrifuged for 7 min at 16,000 × g at 4°C. After centrifugation, 500 μL of the supernatant was combined with an equal volume of water in a capped liquid chromatography (LC)/MS sample vial. LC/MS analysis was performed on an AB Sciex 5500 Q-Trap triple quadrupole MS system coupled with an Agilent 1200 system with refrigerated autosampler. A Waters Exterra 2.1 mm × 50 mm C18 column was used for chromatographic separation, along with an isocratic mobile phase consisting of 50% water and 50% (vol/vol) acetonitrile, with both solvents containing 0.1% (vol/vol) formic acid. The lower limit of quantification was 0.048 μg/mL serum or tissue homogenate. The following parameters were used for concentration determination: for clofazimine, transition, 474/431.9; declustering potential, 231 V; collision energy, 51 V; entrance potential, 10 V. LC/MS reagents, including LC/ MS-grade acetonitrile, molecular-grade formic acid, and the clofazimine standard, were purchased from Sigma. Milli-Q water was used throughout the LC/MS procedure.
Statistical Analyses. cfu counts (x) were log-transformed as (x + 1) before analysis. Group means were compared by two-way ANOVA with the Sidák test to correct for multiple comparisons. Straight-line nonlinear regression with extra sum-of-squares F test was used to compare the slope of the decline in mean cfu counts in the lungs and spleens. All statistical analyses were performed using GraphPad Prism software, version 6.01.
